Biorthex sells SpineCor to focus on Actipore:
This article was originally published in Clinica
Canadian company Biorthex has sold the exclusive worldwide licensing rights for its SpineCor flexible bracing system to The SpineCorporation of the UK. The move will allow the Montreal company to concentrate on its porous biomaterial, Actipore. Biorthex says the technology will lead to a new generation of surgical implants. "We believe that the Actipore material has a promising future and we want to maximise the company's focus on this new line of products," said Sylvain Gareau, Biorthex's CEO.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.